AI-CVD is a quantitative imaging tool that uses computed tomography images to identify and quantify a myriad diseases. 

The newest addition to the company's Farapulse PFA Platform was specifically approved to perform cavotricuspid isthmus ablation. 

American College of Radiology Chief Executive Officer Dana Smetherman, MD, explains the highlights of the recent BI-RADS Version 2025 release, the first update in more than a decade.
 

The device at the heart of this transaction is the PerQseal Elite system, a fully bioabsorbable patch for percutaneous vessel closure. The technology has already gained key approvals in Europe. 

A new comprehensive report detailed the latest stats and trends in hypertension, coronary heart disease, stroke and many other areas of interest. “Progress in cardiovascular health depends on knowing where we stand,” the authors wrote. “To improve, we must measure—not occasionally, but consistently, transparently and with purpose.”

SCCT has made it a priority to help clinicians from all over the world learn more about CCTA as the modality continues to transform patient care. 

Bayer is acquiring two cardiac amyloidosis radiotracers from Attralus, one for PET and one for SPECT. The SPECT tracer is also a theranostic agent to both image and treat amyloidosis.

CMS previously announced it was temporarily reassigning payment codes for coronary CT angiography, resulting in a 104% higher technical fee. 

Previous research has shown that resistance to medical AI may be caused by difficulty in understanding both algorithms and human decision-making in healthcare. 

The company has reached a deal to purchase two investigational imaging agents from Attralus Inc., a Naples, Florida-based biopharmaceutical firm.